Rossari Biotech
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Rossari Biotech's management has articulated a clear focus on margin expansion and operational efficiency following significant capital expenditures. The company anticipates a 15% revenue growth in FY27, driven by improved ethylene oxide (EO) availability and strategic investments, including a new facility in Saudi Arabia. This optimism is supported by a disciplined capital allocation strategy and a commitment to enhancing their core B2B business, which continues to outperform the broader market. However, challenges such as raw material volatility and geopolitical uncertainties remain pertinent. Vista's financial outlook reflects stable revenue growth and margins, aligning with management's projections. The company's balance sheet remains conservatively financed, providing a solid foundation for future growth. Industry dynamics, including structural growth in specialty chemicals and competitive pressures, further influence Rossari's outlook. Over the next 12-24 months, key opportunities include leveraging new capacities and expanding into high-growth markets, while watchpoints include input cost volatility and the performance of the Institutional/B2C segments
Why We Like This Stock
- Management's focus on margin expansion and operational efficiency is expected to drive revenue growth
- Strategic investments, including a new facility in Saudi Arabia, are anticipated to enhance competitive positioning
- The company's strong balance sheet supports its growth initiatives and mitigates financial risk
Things To Watch Out For
- Raw material cost volatility poses a significant risk to profit margins
- Geopolitical uncertainties, particularly related to the Saudi investment, could impact operational stability
- Underperformance in the Institutional/B2C segments may hinder overall growth potential
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,831 | 2,080 | 2,396 | 2,663 | 2,956 |
| Profit Before Tax (Cr.) | 176 | 185 | 203 | 186 | 223 |
| PBT Margin | 9.6% | 8.9% | 847.2% | 7.0% | 7.5% |
| Net Profit (Cr.) | 130 | 126 | 141 | 131 | 156 |
| Earnings Per Share | 23.4 | 22.7 | 25.4 | 23.5 | 28.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Deven Choksey | ▲ Buy | 604 | 30-Apr-2026 |
| ICICI Securities | ▲ Buy | 605 | 21-Jul-2026 |
Company Overview
Show Company Profile
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, India.